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Abstract
This paper uses Hospital Episode Statistics, English administrative data, to investigate the growth in
admitted patient health care expenditures and the implications of an ageing population. We use two
samples of around 40,000 individuals who a) used inpatient health care in the financial year 2005/06
and died by 2011/12 and b) died in 2011/12 and had some hospital utilisation since 2005/06. We use a
panel structure to follow individuals over seven years of this administrative data, containing estimates of
inpatient health care expenditures (HCE), information regarding individuals’ age, time-to-death (TTD),
morbidities at the time of an admission, as well as the hospital provider, year and season of admission.
We show that HCE if principally determined by proximity to death rather than age, and that proximity to
death is itself a proxy for morbidity.
JEL codes: H51; J11; I19.
Keywords: health care expenditures, ageing, time-to-death, morbidity.
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Introduction
There is concern that the demographic pressures of population ageing will lead to an unprecedented
rise in public expenditures to levels unsustainable under current financing arrangements. In the UK in
2013 approximately 17% of the population (11 million individuals) were aged 65 years or over. This
represents a rise of 17.3% in this age group on a decade earlier. Projections suggest that by 2050
this group will have increased disproportionately to younger age groups accounting for approximately
25% of the population (Cracknell 2010)). The growth in the proportion of older individuals is partly due
to increased longevity and partly due to the age structure of the population, particularly ageing of the
generation of baby boomers of the post war period to the early 1970s. Health care expenditures in the UK
have also risen substantially over time both in real terms and proportional to economic growth. Close to
the inception of the National Health Service (NHS) net expenditure (net of patient charges and receipts)
on the UK NHS in 2050/51 was £11.7b (GBP, in 2010/11 prices); representing 3.5% of Gross Domestic
product (GDP). This rose to £121.3b in 2010/11; approximately 8.2% of GDP. Over the twenty-five year
period from 1999/00 to 2014/15 expenditure in England has almost doubled to £103.7b (2010/11 prices)
with an average expenditure per head of population of £1,900 (Harker 2012). Abstracting from issues
such as technological innovation, the concern is that as the share of the population at older ages rises,
the economic burden of providing healthcare will become increasingly unsupportable.
Interest in the link between ageing populations and health care expenditures can be traced back 25 years
when the International Monetary Fund (IMF) asserted that ‘demographic pressures [in the UK] of an aging
population will be associated with increased demand for medical services’, and presented descriptive
statistics from various countries, showing that older patients, on average, had greater health care costs
than younger patients (Heller et al. 1986). A report by the Organisation for Economic Co-operation
and Development (OECD) predicted that across Europe population ageing will create a rise in age-
related social expenditures from around 19% of GDP in 2000 to around 26% by 2050. Old-age pension
payments and expenditure on health and long term care was deemed responsible for approximately half
this increase (Dang et al. 2001). Approaches to predicting expenditure growth vary, but in a simplistic
form consists of computing observed expenditures per head for different age-sex groups and multiplying
by projections of the number of people expected to fall into each group. This approach, however, fails to
consider the underlying drivers of heath care expenditures and the relative role of age, or, as has been
suggested, proximity to death, or underlying levels of disability and ill-health, in determining expenditures
and its likely growth (see Gray (2005)).
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Additional to projections of population ageing is the potential change in the health profile of the population
over time. An ‘expansion of morbidity’ hypothesis has proposed that the ‘net contribution of our successes
has actually been to worsen the people’s health’, as improvements in health care tend to lengthen the
lives of those living with illness disproportionately to the effect of such improvements on the lifespan of
those living without (Gruenberg 2005). Should population ageing occur alongside a deterioration of health
at older ages, then this will exacerbate impacts on public expenditures. While subsequent academic
research into these claims – notably, research in the ‘compression of morbidity’ and ‘red herring’ strands
of literature – have given reason to suggest that such concerns may have been misplaced or exaggerated,
concern over the impact of an ageing population on HCE has persisted. Indeed, even in 2012, the UK’s
then-Secretary of State for Health claimed that the fact that ‘the number of people aged over 85 in this
country will double in the next 20 years’ was one of two factors in ‘costs... rising at an unaffordable rate’
(Lansley 2012). He further argued that ‘age is the principal determinant of health need’1, and that local
NHS budgets should be recalibrated to be based on this, as a result (Williams 2012).
This paper uses UK administrative data from Hospital Episode Statistics (HES), and deaths data from
the Office for National Statistics (ONS), to consider two related research areas. The first, in line with
the ‘red herring’ thesis advanced by Zweifel et al. (1999), is to explore the determinants of health care
expenditures, with particular attention to the role played by age, time-to-death (TTD), and morbidity. We
do this in a unique way by following samples of individuals who died in England, over seven years of
HES data from 2005/06 to 2011/12, and constructing a panel on individual health care expenditures and
morbidity over this period. We show that TTD dominates age as a key driver of health care expenditures
and morbidity characteristics dominate TTD. This finding extends the ‘red herring’ literature by showing
that TTD is itself a ‘red herring’ and acts as a proxy for morbidity. This links to a second area of research
by locating the modelling of health care expenditures for individuals close to death within the broader
literature on prospective prediction of hospital use to inform resource allocation, particularly those based
on individual level data and which incorporate information on morbidity (for example, see Dixon et al.
(2011)).
Compression of morbidity
The ‘compression of morbidity’ strand of literature beginning with Fries (1980) suggests that, ‘[i]n its
simplest form, “the age at first appearance of symptoms of aging and chronic disease can increase more
rapidly than life expectancy”’ (Fries et al. 2011). Fries (2005) identifies three separate ‘eras’ of illness and
well-being experienced during the 20th Century and beyond: an era of infectious disease, followed by
1 Emphasis ours.
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an era of chronic disease, followed by an era described by the author as ‘directly related to the process
of senescence, where the aging process itself, independent of specific disease, will constitute a major
burden of disease’. Senescence – the process of ageing – is characterised by the ‘decline of maximal
function of [all] vital organs’, beginning before any chronic disease takes hold: deaths where this function
declines below a level necessary to sustain life, in the absence of any disease occasioning this, may be
termed ‘natural deaths’ (Fries 2005).
The implications for HCE of an ageing population become less clear in the light of compression of
morbidity, and there are two aspects to this which deserve attention. First, as the “age at first appearance
of symptoms of aging and chronic disease” increases, individuals can be said to age more healthily:
the implications of this for HCE are considered below. Second, the compression of morbidity thesis
takes for granted an increase in life expectancy. The implications of this for HCE can be considered at a
population level for any given year of spending. Setting aside the causal process for this health ageing
(again, considered below), as the average person ages more healthily, they require lower HCE at any
given age. As more people live to very old age – for instance, 90 years old – each individual requires
lower health spending at that age. The overall picture for HCE is however ambiguous: a larger number of
people requiring lower HCE may require greater overall costs at a population level than a smaller number
of people requiring higher HCE. Similarly, an individual, who dies at age 90 and requires lower HCE at
any given age than they would had they been born into an earlier cohort, may require greater cumulative
HCE over their lifespan than they would had they aged less heathily and died at the age of 70. The
implications for HCE in the presence of healthy ageing and increased lifespan may differ at an individual
level to a population level.
Evidence on compression of morbidity
Freedman et al. (2002), in a systematic review covering research that had been conducted between 1990
and 2002 found that many measures of disability and limitations in old age had seen declines in recent
years: in particular, a change of -1.55% to -0.92% per year in those reporting any disability during the
late 1980s and 1990s. Romeu Gordo (2011) observe a cohort-on-cohort fall in the number of individuals
with high levels of disability-related functional problems in their everyday life for those born between 1924
and 1947 in the US. Cutler et al. (2013), using Medicare records from the US, present evidence of an
increase in disability-free life between 1991 and 2009. The authors conclude that ‘The major question
raised by our results is why this has occurred. How much of this trend is a result of medical care versus
other social and environmental factors?’.
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Cross-country international evidence on the changing patterns of disability rates across nine OECD
countries is provide by Jacobzone et al. (2000). Consistent with the above literature, they report evidence
of significant falls in severe disability rates. The importance of this issue for forecasting HCE depends
upon how changes in mortality, changes in morbidity, and changes in disability occur and interact with
each other. If the onset of chronic conditions – those imposing large costs on health systems – can be
postponed out of an individual’s lifetime, then health care costs may fall as later cohorts enjoy a longer
lifespan, with a reduced level of necessary treatment for chronic conditions.
The morbidity and disability profile of individuals, according to this research, at any given age has
improved over time, leading to health problems being experienced later in life and more closely to
death. In the illustrated case (Figures 1 and 22), individuals live up to a longer observed maximum age
(indicated by the shift out of the survival curve from S1 to S2 in Figure 1), and have a higher observed
level of health at all ages (indicated by the shift out of the health status curve from H1 to H2 in Figure 2).
Both survival curves and health status curves have become increasingly rectangular. The effect on
health care expenditure (HCE) is ambiguous, given that generally more healthy ageing – a decrease
in morbidity at any given age – puts downward pressure on HCE, while an increase in life expectancy,
ceteris paribus, puts upward pressure on HCE. The actual relationship between health care costs and
changes in morbidity and mortality profiles at every given age depends upon the changing shape of these
two curves, and also the extent to which the changes in each are due to or caused by the healthcare that
creates these HCE. The use of age per se in predicting future health care costs should be approached
with caution, as a result.
2 Adapted from Fries (1980) and http://www.aei.org/files/2008/06/27/20080626_WashingtonAEI.pdf.
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Age and time-to-death
The ‘red herring’ strand of literature further gives empirical reason to suggest that claims of steeply-rising
future HCE due to population ageing.3 may have been exaggerated, potentially owing to morbidity being
concentrated in later years of life. Zweifel et al. (1999), using Swiss sickness fund data, finds that no effect
of age on health care expenditures existed after controlling for ‘time-to-death’ (TTD), i.e. the time from any
given point of observation to death for an individual. Owing to the number of individuals with zero HCE,
a two-step model (with a probit first stage and OLS second stage) was employed, with only deceased
patients included in the model. Such work was criticised on the grounds of potential endogeneity, with
time-to-death affected by both present, previous (and, due to the nature of how TTD must be measured)
future HCE. In a subsequent paper, Zweifel et al. (2004) seek to test for such problems, finding that
while TTD is endogenous, their results were ‘fairly robust’ to the error this induces. Werblow et al. (2007)
find that age is a small (but statistically significant) determinant of HCE after controlling for TTD for
patients using long-term care (LTC), such as those in care homes, and is not associated with HCE for
non-LTC patients. More complicated methods, such as those employing generalised linear models, have
since been used, for example by Werblow et al. (2007), in order to deal with the non-normal properties
(such as positive skewness) exhibited in the distribution of HCE. These papers have corroborated results
obtained using probit and OLS two-step models. Felder et al. (2010), in a recent paper in this series, first
predict individuals’ survival based on observed HCE and socioeconomic characteristics (in early waves),
before using predicted values based on this as an instrument for TTD in explaining HCE in later waves.
The authors find that, while TTD cannot be deemed exogenous, any effect of age on HCE becomes
insignificant when TTD (or instrumented TTD) is included in the model.
While use has been made of morbidity markers in models of long-term care expenditures (LTCE) (see
Meijer et al. (2011)), such use has not been made in models explicitly investigating the link between
HCE and population ageing. One possibility is that TTD is itself a red herring, in that it is simply a proxy
for morbidity, unobserved in existing HCE models in the red herring strand of literature. This seems
intuitively plausible: in the years before death, it is likely that morbidity will increase, leading to more
treatment, and that comorbidities complicating the treatment of the disease bringing about the hospital
episode will also increase. Shwartz et al. (1996), in work predating the original red herring hypothesis,
note that the inclusion of variables for comorbidities increase substantially the explanatory power of
models. It seems likely that variables incorporating ‘time-to-death’ in more recent models of HCE are
picking up, in large part, these comorbidities, which are not included in existing HCE models in the red
3 HCE may rise due to technological change brought about by new expensive innovations in health care treatments, or due to shifting
patterns of morbidity.
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herring literature. Indeed, Meijer et al. (2011) conclude that time-to-death ‘largely approximates disability’
in models of LTCE. Dixon et al. (2011), in proposing individual-level formulae for resource allocation in
the UK’s National Health Service (often termed ‘Person-Based Resource Allocation’, or PBRA) include
individual level morbidity markers, finding that these have a ‘powerful effect... in predicting individual level
expenditure’.
The process generating HCE is clearly not a simple function of those explanatory variables used in
existing ’red herring’ research: the actual data-generating process behind these health care expenditures
is unlikely to be characterised accurately by a simple use of age, historical time and time-to-death. In
addition to the aforementioned problems surrounding TTD and age as a proxy for morbidity, as Breyer
et al. (2014) note, many existing models are likely to be characterised with substantial endogeneity
problems, which lead to potential bias in the estimation of the change in HCE as an individual ages or
approaches death. The authors control for potential endogeneity introduced by differential treatment
based on a physician’s view of the patient’s expected health benefits from treatment, proxied by actuarial
tables of life expectancy conditional on age. If physicians expect individuals to respond differently to
treatment, this may cause those who are more likely to respond to treatment to be treated more intensely
than those who are not, thus increasing expected HCE for individuals who are younger, further-from-death
or with fewer comorbidities because of physician selection. Conversely, HCE for older individuals – or,
more likely, individuals in the final years of life – may rise as intensity of treatment becomes stronger with
heroic efforts to save an individual’s life, possibly motivated by ethical ‘rule of rescue’ concerns when
faced with an identifiable, gravely sick individual (Jonsen 1986). Breyer et al. (2014) jointly estimate this
possible physician selection based on life expectancy alongside a model for health care expenditures,
incorporating both age and time-to-death as explanatory variables. They find that increasing survival
rates for the elderly in Germany have positive impacts on HCE, arguing that this is explained by physician
selection: treating patients more intensively if they expect positive results from treatment over a longer
time span.
Datasets used within the ‘red herring’ literature are, in general, sickness fund datasets, with only
Seshamani and Gray (2004) using population-level (for users of NHS treatment) data, the Oxford Record
Linkage Study, a longitudinal dataset of all individuals within an area of Oxfordshire, England. We believe
our paper to be the first to use a sample of individuals from a comprehensive national-level dataset of
health care users.
The extent to which ‘red herring’ and related issues are of interest depends upon the intended use of
such research. Much existing literature focuses on projections of future health care costs given an ageing
population, with the headline results of some papers (such as Stearns and Norton (2004) and Seshamani
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and Gray (2004)) being the overestimation of expected costs for a given future year when TTD is an
omitted variable. This is due to the collinearity between TTD and age for a given individual: an individual
who gets one year closer to death also gets one year older, and so the impact of TTD is picked up by age
in such models. The inclusion of morbidity markers in addition to, or replacing, TTD would allow greater
precision of future estimates where reliable estimates of morbidity prevalence, and the cost of treatments,
conditional on age and TTD were known. Certainly, if the compression of morbidity hypothesis holds,
and individuals are able to postpone the onset of chronic diseases – with associated higher HCE – to a
time period closer to their death, or even indefinitely, explicitly considering morbidity rather than proxying
this by age and/or TTD becomes ever more important.
We build upon the compression of morbidity and red herring strands of existing literature, seeking to
further examine the relationship between ageing, time-to-death and health care expenditures. The
original red herring hypothesis is that, once time-to-death is included in models of HCE, age per se
does not explain changes in HCE. While models intended for resource allocation (Dixon et al. 2011)
have already included morbidity as an explanatory variable in HCE for the general population, other
applications of models of HCE have not – in particular, those focusing explicitly on ageing populations,
or costs in the years approaching death. This paper seeks to bridge the gap between the red herring
strand of literature and models of resource allocation, treating morbidity measures as omitted variables
in models of current health care expenditure, and examining what the relationship between age, TTD
and HCE is once morbidity is included in these models (see, for instance, Aragon et al. (2016)).
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Data
Data sources
Information on patient-level hospital use and associated reference costs for treatment are derived from the
Hospital Episodes Statistics (HES) dataset, published by the Health and Social Care Information Centre
(HSCIC). This is complemented with small-area data on years of potential life lost (YPLL) published by
the ONS, and individual level mortality information, jointly published by the HSCIC and the ONS.
We use successive years (financial years 2005/06 to 2011/12) of the HES dataset, which has been
published for each financial year since 1989/90 and is available for admitted patient care, outpatient,
accident and emergency and maternity cases. The admitted patient (commonly, ‘inpatient’) care HES
dataset that we use provides information on individual-level patient characteristics and diagnoses and
procedures undergone for all patients admitted to hospitals in England.4
Information regarding inpatient spells is used to associate reference costs to each spell. Reference
costs are based on each NHS provider’s estimates of their own costs for each patient spell, categorised
by HRG. These reference costs are derived from accounting costs for each HRG, submitted by each
organisation providing secondary care in England (Department of Health 2012). The NHS Costing
Manual provides guidance to all providers to support the calculation of reference costs and to enforce
more uniform standards for costing methodologies. We use the estimate provided by the hospital
providing treatment as our estimated cost for the patient’s episode. The DH’s Reference Cost data is
submitted on a full absorption basis – that is, taking account of all direct and indirect costs relating to
the activities in question, as well as a proportion of an estimate of all overhead costs relating to the
overall running of the provider. Further, to account for the fact that costs will vary even within HRGs,
hospitals are required to provide per diem costs for longer admissions that exceed a given ‘trim point’,
which differs by each HRG. This trim point is defined as the upper quartile of length of stay, plus 1.5
times the inter-quartile range for length of stay for that HRG (Department of Health 2012). Moreover, we
augment the standard costs incurred in each episode with the ‘unbundled’ costs where recorded for the
episode. This represents one or more extra fixed costs associated with the episode where additional,
unusual, high-cost treatment or procedures were involved. Even within the same primary HRG, costs are
not identical but differ according to the patient’s length of stay. An estimate of costs for each inpatient
4 This dataset includes both daycases (patients without an overnight stay) as well as patients who have at least one night’s stay in
hospital. Our use of ‘inpatient’ throughout this text includes both types of patient.
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spell is obtained by matching data on costs for that provider in the Reference Costs database to HRG for
each episode in the relevant year’s HES data.
HES contains diagnostic data, categorised (since 1995/96) according to the tenth revision of the World
Health Organization’s International Classification of Diseases (ICD-10). Details of procedures and
interventions are recorded according to the fourth revision of the Office of Population, Censuses and
Surveys’ Classification of Intervention and Procedures (OPCS-4) (Health & Social Care Information
Centre 2013).
HES is broken down by completed “episode” – each record consists of a continuous period of care at a
single provider of treatment under the same consultant. A new record is generated when a patient is
either transferred to the care of either a new consultant, transferred to a new provider, or is discharged
from hospital. Although individuals are not identifiable, the hesid variable allows individuals to be tracked
across episodes, to create spells – multiple episodes unseparated by a temporal break outside of hospital.
The costing of a patient’s time in hospital and the recording of their diagnoses and procedures undergone
are made at the episode level.
Patients can be tracked across different years of the HES dataset, which enables the creation of a panel
structure for the data. Information within the HES dataset – most commonly, information regarding
diagnosis, treatment and age of the patient – is used to apply the most appropriate Healthcare Resource
Group (HRG) categorisation to the dataset. We use the Health and Social Care Information Centre’s
Consultation ‘Grouper’ software in order to carry out this first step. We use the most recent version of
this Grouper – for the 2011/12 financial year – for all seven of the years we use, to categorise patients
into HRGs. HRGs are used to categorise patient spells not only by broad diagnosis, but by the type and
complexity of the patient’s spell, into one of over 1,400 groupings. This allows us to apply the current
best-practice methods for grouping patients into HRGs based on the information available. We apply
available estimates of hospital costs for each inpatient spell, using reference costs data for the relevant
financial year.
We add information regarding an individual’s death from linked HES-ONS mortality data. The latest
version of this data provides information on deaths to the end of the 2012 calendar year, and therefore
provides information on some individuals whose deaths are known to have occurred after the end of
the final wave in our dataset. Where individuals are known to have died, they are included up to and
including the final quarter of their life, and not included in the panel in following years. TTD can only be
measured – for decedents – retrospectively, using information available at the time of the individual’s
Health care expenditures, age, proximity to death and morbidity: implications for an ageing population.
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death. We observe individuals for a maximum of seven years (from 2005/06 to 2011/12) or 28 quarters
and code TTD from 1 to 28, with TTD = 1 denoting the final quarter in which death occurs.5
We adopt a strategy that employs two complementary sampling procedures, each incorporating approx-
imately 40,000 individuals. The first draws a sample of individuals who died in 2011/12, the final year
of our analysis, and who had at least one quarter of recorded positive HCE in the 28 quarters of our
data. The second draws a sample of individuals who had at least one quarter of recorded positive HCE
in 2005/06, and died in or before 2011/12. We believe that each of these sampling procedures has
advantages and disadvantages but that, together, they can be used to establish a clear conclusion on
our research question.
Our first sample for analysis consists of a random sample of 39,381 individuals (18,690 men and 20,691
women) aged 50 years and older, taken from those with at least one inpatient episode between 2005/06
and 2011/12, and whose death was recorded by the ONS in the financial year 2011/126. Our second
sample consists of a random sample of 39,796 individuals (19,673 men and 20,123 women) aged 50
years and older, taken from those with at least one inpatient episode in 2005/06, and whose death
was recorded by the ONS after this point, and by the end of the financial year 2011/12. Sample size
was selected to enable computations not to become burdensome, and the age cut-off was selected to
ensure sufficient deaths were observed in the data to make meaningful inference. We follow all sampled
individuals across all quarters until their death to observe their subsequent inpatient health care use and
associated morbidity characteristics.
We collapse all inpatient episodes for each individual from HES for a given quarter into a single
observation in our data. This observation contains the sum of all hospital costs incurred in all episodes
finishing in that quarter, as well as diagnostic information contained in the ICD-10 codes for those
episodes. In principle, the ICD-10 classification allows for up to 14,400 different diagnoses. To make
these more manageable for analysis, however, we collapse this information using the US Agency for
Healthcare Research and Quality’s Clinical Classifications Software (CCS) method to convert ICD-10
codes to CCS codes (US Agency for Healthcare Research and Quality 2009). This reduces the number of
different groupings to a more manageable 260 mutually-exclusive, and clinically meaningful, categories7.
Where individuals do not have any episodes in a quarter, we seprately adopt two distinct methods in order
to deal with such cases. In one approach, they are recorded as having zero hospital costs, and as having
zero observed morbidities arising from diagnostic information. In the absence of additional information on
5 Coding TTD in this way is akin to assuming all deaths occur at the end of a quarter.
6 This falls to 11,809 men and 16,343 women after the exclusion of the first four quarters, inclusion upon which sampling is
conditional.
7 A full list of these CCS groupings is provided in Appendix A
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the gravity of any residual health problem, this assume that such health issues are insignificant relative
to those leading to a hospitalisation. In a second approach, we recognise that the recording of zero
morbidities might be unrealistic for patients observed to have hospitalisations in recent periods and for
whom there is likely to exist an underlying, albeit less grave, health problem. Consequently, we model
these cases in our second approach under the assumption that episodes for which no information is
available represent non-informative, missing data.
While we include a sum of all hospital costs for episodes ending in the quarter in question, we include
only a maximum of three diagnoses for each individual, for a maximum of five episodes ending in that
quarter. Using the merged mortality data, we are able to add a variable for the individual’s time-to-death,
measured in number of quarters to death.
In addition, we make use of the Office for National Statistics’ Indices of Multiple Deprivation (IMD), by
Lower Super Output Area (LSOA) in order to construct an instrument for TTD. LSOAs are defined at the
time of the UK’s decennial Census and are made up of similarly-sized small areas of the country. HES
data, for the years used in our dataset, provides information on the individual’s LSOA of residence at
the time of the 2001 Census. At this time, LSOAs in England consisted of 32,482 areas of populations
between 1,000 and 3,000, with between 400 and 1,200 households (Office for National Statistics 2011).
Indices of Multiple Deprivation, at this LSOA level, are measures of the levels of deprivation in those
small areas. Although made up of seven domains (income, employment, health and disability, education,
housing, living environment and crime (Department for Communities and Local Government 2011)), we
primarily make use of one of the indicators that forms part of the health and disability IMD score: years
of potential life lost (YPLL). This consists of a standardised measure of premature mortality calculated
using information for all individuals to have died before the age of 75, as described in Blane and Drever
(1998)89. Although the LSOAs themselves are defined every ten years at the time of the UK’s census,
statistics for each domain are collected and published for these areas more regularly: we make use of
those published in 2007 (produced using data from 2001-2005 inclusive), and 2010 (produced using
data from 2004-2008 inclusive) (Department for Communities and Local Government 2008; Department
for Communities and Local Government 2011). For each of these years, we use LSOAs as defined in
the 2001 UK Census. While these figures are comparable within years, the data collector (the UK’s
Department for Communities and Local Government) caution against using this data for trend analysis.
These measures are highly correlated with TTD and, by virtue of being calculated at an aggregate level,
8 The Office for National Statistics, however, use 75 rather than 65 years, in their implementation of this method, as the age at which
mortality is considered to be premature (Department for Communities and Local Government 2011).
9 Details of the method employed by the ONS were obtained in personal communication with the study’s author, Chris Dibben.
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exogenous in a model of HCE. That is, while the level of YPLL at an LSOA level is a strong predictor of
an individual’s TTD, this YPLL level is not influenced by the HCE for a given individual. We therefore
include at least one wave of this measure separately as instruments.
Tables 1 to 2 present descriptive statistics for the sample of decendents from the first wave of data, under
our strategy of sampling from the first year of observations (2005/06). Tables 3 to 4 present descriptive
statistics from the first wave of data, under our strategy of sampling from the final year of observations
(2011/12).
Table 1: Summary statistics (Quarter 1, men, first year sample.)
Variable Mean Std. Dev. Min Max
HCE [missing treated as zero] 475.60 1740.26 0 82901.09
log(HCE) [missing treated as zero] 1.57 3.00 0 11.32
log(HCE) [missing treated as missing] 7.19 1.01 3.42 11.32
Quarters to death (QTD) 9.53 7.77 0 27
log(QTD) 2.02 0.88 0 3.33
Age 75.03 10.24 50 105.66
YPLL (IMD 2007) 65.50 15.71 33.80 180.8
Table 2: Summary statistics (Quarter 1, women, first year sample.)
Variable Mean Std. Dev. Min Max
HCE [missing treated as zero] 504.42 1629.34 0 45095.81
log(HCE) [missing treated as zero] 1.56 3.03 0 10.71
log(HCE) [missing treated as missing] 7.30 0.99 3.39 10.71
Quarters to death (QTD) 9.86 7.89 0 27
log(QTD) 2.05 0.89 0 3.33
Age 78.11 10.93 50 111.15
YPLL (IMD 2007) 65.85 15.54 33.30 191.5
Table 3: Summary statistics (Quarter 1, men, final year sample.)
Variable Mean Std. Dev. Min Max
HCE [missing treated as zero] 220.74 1339.96 0 66770.92
log(HCE) [missing treated as zero] 0.61 2.05 0 11.11
log(HCE) [missing treated as missing] 7.28 1.08 3.85 11.11
Quarters to death (QTD) 25.57 1.13 24.00 27.00
log(QTD) 3.28 0.04 3.22 3.33
Age 72.93 9.82 50 100.83
YPLL (IMD 2007) 64.14 15.09 33.80 162.90
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Table 4: Summary statistics (Quarter 1, women, final year sample.)
Variable Mean Std. Dev. Min Max
HCE [missing treated as zero] 213.89 1310.72 0 64392.08
log(HCE) [missing treated as zero] 0.56 1.98 0 11.07
log(HCE) [missing treated as missing] 7.36 1.08 3.34 11.07
Quarters to death (QTD) 25.59 1.13 24.00 27.00
log(QTD) 3.28 0.04 3.22 3.33
Age 76.80 10.02 50 105.58
YPLL (IMD 2007) 64.78 15.07 33.80 180.80
As is usual, the distribution of HCE is positively skewed, with this skewness reduced somewhat when
we take a logarithmic transformation.10 As would be expected due to their longer lifespan, on average,
the average age of women in the sample is somewhat higher than that for men. Similarly, women
are observed for, on average, slightly more waves. HCE, with missing waves treated as zero-cost
observations, is on average higher when sampling from the first financial year of data than when sampling
from those who died in the final year of analysis. This is as expected: the former is drawn from those
with an inpatient episode in 2005/06, whereas the latter is drawn from those with an inpatient episode in
any of the seven financial years of analysis. Indeed, HCE is approximately similar when missing waves
are treated as missing observations.
Diagrams, presented in Figures 3 and 4, based on descriptive statistics, treating waves with no observa-
tions as missing, provide some illustration of the existing red herring thesis. HCE appear to increase
with age (top-left panel): this is the usual age-expenditure curve that is used to infer rising costs with
population ageing. The assumption being that as the population ages, ignoring the drop in expenditures
at very high ages as this is likely due to low sample sizes, the curve continues to rise as an extrapolation
of the observed trend. The observation that expenditures rise with age, however, is an artifact of a
compositional effect. The naïve age-expenditure curve is composed of individuals who are known to
have died during the period of observation (the sample used in estimation) – who have, on average,
high expenditures for this period (top-right panel) – and individuals who are known to have survived
who have, on average, lower expenditures for this period (bottom-left panel). The average expenditures
for individuals observed to have died during the sample period are far greater than for individuals who
survive. This suggests an important role for time-to-death in explaining HCE. As the proportion of the full
population who are decedents increases with age, the näive observed relationship between age and
expenditure displays an increasing trend. Note, however, that average expenditures for both decedents
10Due to log(0) being undefined, we add a value of one to such observations in our modelling strategies that include zero-cost
quarters.
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and survivors display a flatter profile than that depicted for the full population suggesting a less important
role for age. Indeed, expenditure on decedents generally decrease, with this decrease particularly
pronounced for women. Expenditure on survivors generally increase, but with a shallower gradient than
observed for the full population, and at a lower average cost.
When we focus on decedents, and consider average HCE by proximity to death, we observe a large
increase in costs in terminal quarters – particularly in the year immediately before death. Figure 7 in
the Appendix shows a similar relationship between expenditures and TTD for men at selected ages.
In general, expenditure in quarters preceding the final three average around £500 (although there is
variation). In the final three quarters, and particularly the final quarter, we observed a large increase in
expenditure. With the exception of 50 year olds, there is a clear gradient of health expenditures rising
most dramatically in the final quarter of life with average increases over the penultimate quarter ranging
from £460 for 55 year olds to £1,099 for 90 year olds.
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Figure 3: Healthcare expenditures by age and proximity to death, males
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Figure 4: Healthcare expenditures by age and proximity to death, females
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The relationship between HCE and TTD in levels is nonlinear. Figure 5 shows that the relationship is
approximately linear on the logarithmic scale and in the modelling that follows logarithms of both HCE
and TTD are used throughout.
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Figure 5: Average health care expenditures according to quarters to death (log scale for x- and y-
axes)
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Econometric model
We follow the general strand of the red herring literature and specify a baseline model of HCE, including
only age as an explanatory variable.
log (HCEit) = α+ βageageit + τit + µi + εit, i = 1, ..., N, t = 1, ..., Ti, (1)
where τit is a vector of control variables (year and season of admission, and hospital provider dummies)
µi is an individual-specific unobserved effect and εit is an idiosyncratic error term. Although this model is
not estimated in existing papers, it is claimed that such a model would not adequately explain HCE. TTD
is claimed to be an omitted variable in these models, giving rise to models such as:
log (HCEit) = α+ βageageit + βTTDlog (TTDit) + τit + µi + εit. (2)
We argue that individual morbidity is an omitted variable in this type of model. Accordingly, we augment
the model as follows:
log (HCEit) = α+ βageageit + βTTDlog (TTDit) +
260∑
j=1
βCCSjCCSjit + τit + µi + εit, (3)
where CCSn represents a recorded morbidity of CCS type n (n = 1...260). We exploit the available data
in HES to include detailed information about a patient’s morbidities at the time of their hospital stay. We
estimate each of these models with random effects, representing unobserved heterogeneity.
Modelling HCE as a function of TTD suffers from potential problems of endogeneity. Existing literature
suggests that conditional on other covariates, being further from death – i.e. having a high TTD – in
time period t is likely to lead to lower levels of HCE in t. Higher levels of HCEit, however, are likely to
lead to high levels of TTDit: if the hospital activity that generates health care expenditures is effective in
improving health then the individual is likely to enjoy a longer remaining lifespan as a result. We therefore
posit that actual TTD at time period t has been determined in part by HCE in that time period as well as
other time periods. Consequently, if endogeneity does pose problems in this analysis, the coefficient
estimate on TTD (when treated as exogenous) is likely to be an underestimate of the true ‘effect’ of TTD.
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Other models in the red herring strand of literature model HCE, using TTD and age as explanatory
variables, but highlighting this endogeneity problem. Various attempts are made to purge TTD of its
endogeneity in HCE (Zweifel et al. 2004; Werblow et al. 2007; Felder et al. 2010). We propose the use of
a component of the Health and Disability Index of Multiple Deprivation by Lower Super Output Area –
years of potential life lost (YPLL) – as an instrument for TTD under the assumption that such measures
are exogenous in a model of HCE but highly correlated with TTD. That is, while the level of YPLL at an
LSOA level is a strong predictor of an individual’s TTD, this YPLL level is not influenced by the HCE for a
given individual. Accordingly, where possible, we reestimate models (2) and (3) instrumenting TTD by
YPLL. Such an instrumented approach is, however, possible only in the case of our second sampling
procedure, where TTD is not pre-determined by the construction of the sample. In our former sampling
procedure, all individuals die in the final four quarters (i.e., final financial year) of the sample, and thus
any relevance of variation across areas in deprivation would not be expected.
Health care expenditures, age, proximity to death and morbidity: implications for an ageing population.
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Results
All versions of our different sampling and modelling strategies lead to qualitatively similar results. In
short, a weak (and often statistically insignificant) relationship is observed when costs are modelled as
a function of age alone. Confirming the overall red herring results, a strongly significant relationship
is observed between TTD and HCE, when TTD is added as an explanatory variable. This is in line
with our descriptive diagrams (Figures 3 & 4), demonstrating that the naïvely-estimated relationship
between age and HCE is muted when conditioning on TTD. When morbidities are included as explanatory
variables, the relationship between TTD and HCE is reduced (in all cases, the coefficient is reduced by
approximately two-thirds). When, where possible, instrumenting TTD, the relationship between TTD and
age becomes larger, with the addition of morbidities again reducing the size of the TTD cofficient.11
Table 5 presents the results of various specification of a random effects panel data model of log(HCE) on
age, log(TTD) and morbidity characteristics for the sub-sample of decedents, when a sample is drawn
from those who died in 2011/12. The first column of results (model 1) shows a weak and generally non-
significant relationship between age and inpatient costs. These results represent, as far as we are aware,
the first reported results in the red herring strand of literature of whether hospital costs increase with age
in the aggregate, even before control is made for other factors such as TTD and morbidities. Existing
research broadly states that this is the case, but refer merely to population-level descriptive statistics. In
a random effects model (2) including TTD and age, we observe a highly significant relationship with TTD.
This result is in line with those in the red herring strand of existing research. As an individual gets 1%
closer to death, HCE increases by between 0.34% and 0.42% for men (between 0.28% and 0.34% for
women), depending on the modelling strategy adopted12.
11All results presented here employ one wave of the YPLL instrument. Where both instruments appear as relevant at the first stage,
we estimate the models using both YPLL waves in order to carry out a Hansen J test of the validity of overidentifying restrictions.
In all cases, we observe large p-values consistent with failing to reject the null-hypothesis, suggesting evidence in favour of the
exogeneity of our chosen instruments. Furthermore, our second stage results suggest very similar coefficients and confidence
levels, such that none of our conclusions drawn below are affected.
12Because we aggregate costs by quarter and consequently use discrete values of TTD for each individual in each wave, this
elasticity can only be considered as an approximation.
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Table 5: Results, final wave sampling.
Missing observations treated as missing
Model (1) (2) (3)
AGE_ONLY AGE_TTD AGE_TTD_MORBS
Men
Age -.01459** -.01274* -.00518
(.00654) (.00652) (.00526)
Age2 .00010** .00009** .00003
(.00004) (.00004) (.00003)
log(TTD) -.42375*** -.14454***
(.01467) (.01206)
Morbidities included
Women
Age -.00068 .00081 -.00038
(.00588) (.00585) (.00474)
Age2 .00004 .00003 .00001
(.00004) (.00004) (.00003)
log(TTD) -.34305*** -.13276***
(.01458) (.01218)
Morbidities included
Missing observations treated as zeros
Model (1) (2) (3)
Men
Age .00130 .00204 .00289*
(.00180) (.00181) (.00156)
Age2 0.00000 -.00001 -.00002**
(.00001) (.00001) (.00001)
log(TTD) -.33712*** -.10645***
(.00679) (.00560)
Morbidities included
Women
Age .00983*** .01087*** .00559***
(.00189) (.00189) (.00154)
Age2 -.00005*** -.00006*** -.00003***
(.00001) (.00001) (.00000)
log(TTD) -.27927*** -.09789***
(.00604) (.00520)
Morbidities included
* p<0.05 ** p<0.01 *** p<01
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Table 6: Results, first wave sampling.
Missing observations treated as missing
Model (1) (2) (3) (4) (5)
Men
AGE_ONLY AGE_TTD AGE_TTD_MORBS AGE_TTDIV AGE_TTDIV_MORBS
Age -.01800* -.00454 .00290 -.00953 -.01124
(.00932) (.00896) (.00746) (.02617) (.01087)
Age2 .00013** .00003 -.00002 .00007 .00007
(.00006) (0.00006) (.00005) (.00018) (.00008)
log(TTD) -.31565*** -.10098*** -.35626 -.13120
(.00655) (.00616) (.36994) (.30968)
Joint F-test of relevance (p-value) 0.0000 0.0003
Morbidities included included
Women
Age -.00269 .01198 .00065 .08939 -.01118
(.00832) (.00813) (.00696) (.06773) (.01124)
Age2 .00004 -.00005 -.00001 -.00059 .00007
(.00005) (.00005) (.00004) (.00047) (.00009)
log(TTD) -.26423*** -.09307*** -1.82773 -.12894
(.00663) (.00612) (1.2711) (.3239383)
Joint F-test of relevance (p-value) 0.0000 0.0006
Morbidities included included
Continued on next page
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Missing observations treated as zeros
Model (1) (2) (3) (4) (5)
Men
Age -.06500*** .10191*** -.00691 .28057*** .03547
(.02465) (.02265) (.01462) (.09001) (.06062)
Age2 .00049*** -.00088*** .00001 -.00363*** -.00036
(.00016) (.00015) (.00010) (.00113) (.00058)
log(TTD) -1.19842*** -.18669*** -2.05176*** -.31020
(.01205) (.00745) (.38267) (.23856)
Joint F-test of relevance (p-value) 0.0000 0.0000
Morbidities included included
Women
Age .06863*** .08155*** .02635*** .61590 .05830
(.00928) (.00934) (.00806) (.40329) (.05937)
Age2 -.00039*** -.00048*** -.00016*** -.00393 -.00038
(.00928) (.00006) (.00005) (.00261) (.00040)
log(TTD) -.15705*** -.03723*** -6.43066 -.64920
(.00801) (.00716) (4.95179) (.8581702)
Joint F-test of relevance (p-value) 0.0000 0.0000
Morbidities included included
* p<0.05 ** p<0.01 *** p<01
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Conditioning on morbidity markers, we find a reduced role for TTD in explaining HCE, using both sampling
strategies. Our estimate of the TTD elasticity of HCE falls by approximately two-thirds in almost all
(non-IV) cases when we condition on the individual’s observed morbidity in the current time period (i.e.,
when we move from model 2 to model 3). In all models, in excess of 90% of the estimated coefficients for
the morbidity indicators are significant at the 1% level, yielding a p-value of 0.0000. We interpret this as
indicating that TTD does indeed serve as a proxy for unobserved morbidity. The estimated coefficients
for age when morbidity markers are included see similar falls. This is illustrated in Figure 6 which shows
the difference in log (HCE) from the quarter of death to preceding quarters for an individual who dies at
age 75 for the alternative specifications of the model. The combined relationship of time-to-death and
age is severely muted when we condition on current morbidity markers as seen by the lines representing
RE_AGE_TTD_MORBS and RE_AGE_TTD.
We anticipate hospital costs to rise as individuals approach death, and as such expect a negative
relationship between TTD and HCE. For the sampling strategy where this is possible – sampling from the
first calendar year – we instrument for TTD in order to deal with the potential endogeneity of TTD in HCE,
which would mean that a naïve estimate of the ‘effect’ of TTD on HCE was likely to be biased towards
zero (i.e. that naïve estimates would be expected to be less negative). In a further pair of models, we
instrument TTD with LSOA-level YPLL measures, our small-area measure of premature mortality.
When we instrument using YPLL measures – model (4) – the estimated coefficient of log(TTD) rises
(in absolute terms) in all cases. While we confirm the findings of Zweifel et al. (2004) that ‘the proximity
of death rather than age [being] a main determinant of HCE is fairly robust to endogeneity error,’ our
results also suggest that failing to account for the endogeneity of TTD in these models may lead to a
large underestimate of the true ‘effect’ of TTD in models that do not include morbidity markers. This is
also illustrated in Figure 6, which shows the large divergence in estimated costs for these two models
for an individual who dies at the age of 75. First-stage regressions show, as expected, a negative and
significant relationship between YPLL and TTD and an F-test of these instruments strongly suggests
their relevance as a predictor of TTD (with p-values of between 0.0000 and 0.0006 obtained).
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Figure 6: Change in HCE according to time-to-death and age, hypothetical individual dying at 75
(top – men, bottom – women)
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Conclusions
Ageing populations pose a substantial problem for public service provision, particularly for health and
social care. Estimates of how an ageing population will impact HCEs vary considerably. Developing
credible predictions is a core component of health systems planning as is allocating resources efficiently
and equitably to meet the health care needs of the population. Whilst it is undeniable that health care
costs will rise as the baby-boomers age, the impact might not be quite as large as models based on a
simple extrapolation of a crude age-expenditure curve suggests. As individuals live longer, all other things
equal, they may generate larger cumulative life-time costs. The extent to which this becomes a burden
on the health care sector will depend on how morbidity profiles of cohorts change over time. Should
a compression of morbidity thesis hold, Fries (1980), Freedman et al. (2002) & Romeu Gordo (2011),
on average individuals can expect to live longer and delay the onset of morbidity into later years. This
will have the effect of moving the age-expenditure curve to the right as populations age. An expansion
of morbidty would have more severe consequences for HCEs with individuals living longer, but also
experiencing a greater number of years in ill-health.
Our findings support other literature that it is not age per se, but time-to-death (TTD), particularly the
final year of life, that is a strong driver of HCEs. We extend this literature by showing that TTD in large
part proxies for morbidity. Our results - showing a weak relationship between HCE and age when TTD
is included - fall in line with existing research into the determinants of HCE for ageing populations.
However, while TTD clearly plays an important role in explaining HCEs, it is unhelpful in forecasting future
expenditure needs. At an individual level TTD is unknown an hence to forecast future expenditure growth
assumptions about the proportions of decedents and survivors together with projections of populations
within age groups is required. By extending the modelling of HCE to include morbidity characteristics we
show that the impact of TTD is diminished indicating that it acts as a proxy for underlying health status.
This is important to allow the planning of future resource requirements and in developing appropriate
models for budgets to be allocated equitably across providers of care in response to population health
care need. Our results are robust to problems of endogeneity that exist between HCE and TTD.
Our results strengthen the need to include measures of morbidity in models of HCE. Merely including
TTD is insufficient in predicting future HCE. To accurately forecast future expenditure needs, information
on changes to profiles of morbidity are required. The existence of a compression of morbidity, along with
a tendency for increased life expectancy, suggests competing and opposing pressures on HCE. While
increases in life expectancy suggests that a greater number of individuals will be alive at any given age,
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with associated upward pressure on HCE, a compression of morbidity will tend to, on average, provide
downward pressure on HCE for any given individual at any given age.
This work has focused on determinants of the demand for inpatient health care services at an individual
level via age, time-to-death and morbidity characteristics. Clearly there is also a substantial role for
supply-side impacts on expenditure growth notably through technological advances in health care
interventions and the way in which health care services are organized and delivered. We do not address
these issues here, but are areas that warrant further investigation at an aggregate level. Inpatient hospital
care is one of a number of services provided by the National Health Service in England and other
expenditure should also be taken into account when assessing the overall impact of an ageing population,
as should costs placed on the Government by long-term care services predominantly accessed by older
age groups. The increasing ability to link administrative sources of data provides a potentially valuable
resource for future research in this area.
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Appendix
Table A1: Clinical Classifications Software (CCS) groupings
CCS code Description
1 Tuberculosis
2 Septicemia (except in labor)
3 Bacterial infection; unspecified site
4 Mycoses
5 HIV infection
6 Hepatitis
7 Viral infection
8 Other infections; including parasitic
9 Sexually transmitted infections (not HIV or hepatitis)
10 Immunizations and screening for infectious disease
11 Cancer of head and neck
12 Cancer of esophagus
13 Cancer of stomach
14 Cancer of colon
15 Cancer of rectum and anus
16 Cancer of liver and intrahepatic bile duct
17 Cancer of pancreas
18 Cancer of other GI organs; peritoneum
19 Cancer of bronchus; lung
20 Cancer; other respiratory and intrathoracic
21 Cancer of bone and connective tissue
22 Melanomas of skin
23 Other non-epithelial cancer of skin
24 Cancer of breast
25 Cancer of uterus
26 Cancer of cervix
27 Cancer of ovary
28 Cancer of other female genital organs
29 Cancer of prostate
30 Cancer of testis
31 Cancer of other male genital organs
32 Cancer of bladder
33 Cancer of kidney and renal pelvis
34 Cancer of other urinary organs
35 Cancer of brain and nervous system
36 Cancer of thyroid
37 Hodgkin‘s disease
38 Non-Hodgkin‘s lymphoma
39 Leukemias
40 Multiple myeloma
41 Cancer; other and unspecified primary
42 Secondary malignancies
43 Malignant neoplasm without specification of site
44 Neoplasms of unspecified nature or uncertain behavior
45 Maintenance chemotherapy; radiotherapy
46 Benign neoplasm of uterus
47 Other and unspecified benign neoplasm
48 Thyroid disorders
49 Diabetes mellitus without complication
50 Diabetes mellitus with complications
51 Other endocrine disorders
52 Nutritional deficiencies
53 Disorders of lipid metabolism
54 Gout and other crystal arthropathies
55 Fluid and electrolyte disorders
Continued on next page
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56 Cystic fibrosis
57 Immunity disorders
58 Other nutritional; endocrine; and metabolic disorders
59 Deficiency and other anemia
60 Acute posthemorrhagic anemia
61 Sickle cell anemia
62 Coagulation and hemorrhagic disorders
63 Diseases of white blood cells
64 Other hematologic conditions
65 Mental retardation
66 Alcohol-related mental disorders
67 Substance-related mental disorders
68 Senility and organic mental disorders
69 Affective disorders
70 Schizophrenia and related disorders
71 Other psychoses
72 Anxiety; somatoform; dissociative; and personality disorders
73 Preadult disorders
74 Other mental conditions
75
Personal history of mental disorder; mental and behavioral problems;
observation and screening for mental condition
76
Meningitis (except that caused by tuberculosis or sexually transmitted
disease)
77
Encephalitis (except that caused by tuberculosis or sexually transmitted
disease)
78 Other CNS infection and poliomyelitis
79 Parkinson‘s disease
80 Multiple sclerosis
81 Other hereditary and degenerative nervous system conditions
82 Paralysis
83 Epilepsy; convulsions
84 Headache; including migraine
85 Coma; stupor; and brain damage
86 Cataract
87 Retinal detachments; defects; vascular occlusion; and retinopathy
88 Glaucoma
89 Blindness and vision defects
90
Inflammation; infection of eye (except that caused by tuberculosis or
sexually transmitteddisease)
91 Other eye disorders
92 Otitis media and related conditions
93 Conditions associated with dizziness or vertigo
94 Other ear and sense organ disorders
95 Other nervous system disorders
96 Heart valve disorders
97
Peri-; endo-; and myocarditis; cardiomyopathy (except that caused by
tuberculosis or sexually transmitted disease)
98 Essential hypertension
99 Hypertension with complications and secondary hypertension
100 Acute myocardial infarction
101 Coronary atherosclerosis and other heart disease
102 Nonspecific chest pain
103 Pulmonary heart disease
104 Other and ill-defined heart disease
105 Conduction disorders
106 Cardiac dysrhythmias
107 Cardiac arrest and ventricular fibrillation
108 Congestive heart failure; nonhypertensive
109 Acute cerebrovascular disease
110 Occlusion or stenosis of precerebral arteries
111 Other and ill-defined cerebrovascular disease
112 Transient cerebral ischemia
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113 Late effects of cerebrovascular disease
114 Peripheral and visceral atherosclerosis
115 Aortic; peripheral; and visceral artery aneurysms
116 Aortic and peripheral arterial embolism or thrombosis
117 Other circulatory disease
118 Phlebitis; thrombophlebitis and thromboembolism
119 Varicose veins of lower extremity
120 Hemorrhoids
121 ther diseases of veins and lymphatics
122
Pneumonia (except that caused by tuberculosis or sexually transmitted
disease)
123 Influenza
124 Acute and chronic tonsillitis
125 Acute bronchitis
126 Other upper respiratory infections
127 Chronic obstructive pulmonary disease and bronchiectasis
128 Asthma
129 Aspiration pneumonitis; food/vomitus
130 Pleurisy; pneumothorax; pulmonary collapse
131 Respiratory failure; insufficiency; arrest (adult)
132 Lung disease due to external agents
133 Other lower respiratory disease
134 Other upper respiratory disease
135 Intestinal infection
136 Disorders of teeth and jaw
137 Diseases of mouth; excluding dental
138 Esophageal disorders
139 Gastroduodenal ulcer (except hemorrhage)
140 Gastritis and duodenitis
141 Other disorders of stomach and duodenum
142 Appendicitis and other appendiceal conditions
143 Abdominal hernia
144 Regional enteritis and ulcerative colitis
145 Intestinal obstruction without hernia
146 Diverticulosis and diverticulitis
147 Anal and rectal conditions
148 Peritonitis and intestinal abscess
149 Biliary tract disease
150 Liver disease; alcohol-related
151 Other liver diseases
152 Pancreatic disorders (not diabetes)
153 Gastrointestinal hemorrhage
154 Noninfectious gastroenteritis
155 Other gastrointestinal disorders
156 Nephritis; nephrosis; renal sclerosis
157 Acute and unspecified renal failure
158 Chronic renal failure
159 Urinary tract infections
160 Calculus of urinary tract
161 Other diseases of kidney and ureters
162 Other diseases of bladder and urethra
163 Genitourinary symptoms and ill-defined conditions
164 Hyperplasia of prostate
165 Inflammatory conditions of male genital organs
166 Other male genital disorders
167 Nonmalignant breast conditions
168 Inflammatory diseases of female pelvic organs
169 Endometriosis
170 Prolapse of female genital organs
171 Menstrual disorders
172 Ovarian cyst
173 Menopausal disorders
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174 Female infertility
175 Other female genital disorders
176 Contraceptive and procreative management
177 Spontaneous abortion
178 Induced abortion
179 Postabortion complications
180 Ectopic pregnancy
181 Other complications of pregnancy
182 Hemorrhage during pregnancy; abruptio placenta; placenta previa
183 Hypertension complicating pregnancy; childbirth and the puerperium
184 Early or threatened labor
185 Prolonged pregnancy
186
Diabetes or abnormal glucose tolerance complicating pregnancy; child-
birth; or the puerperium
187 Malposition; malpresentation
188 Fetopelvic disproportion; obstruction
189 Previous C-section
190 Fetal distress and abnormal forces of labor
191 Polyhydramnios and other problems of amniotic cavity
192 Umbilical cord complication
193 OB-related trauma to perineum and vulva
194 Forceps delivery
195 Other complications of birth; puerperium affecting management of mother
196 Normal pregnancy and/or delivery
197 Skin and subcutaneous tissue infections
198 Other inflammatory condition of skin
199 Chronic ulcer of skin
200 Other skin disorders
201
Infective arthritis and osteomyelitis (except that caused by tuberculosis or
sexually transmitted disease)
202 Rheumatoid arthritis and related disease
203 Osteoarthritis
204 Other non-traumatic joint disorders
205 Spondylosis; intervertebral disc disorders; other back problems
206 Osteoporosis
207 Pathological fracture
208 Acquired foot deformities
209 Other acquired deformities
210 Systemic lupus erythematosus and connective tissue disorders
211 Other connective tissue disease
212 Other bone disease and musculoskeletal deformities
213 Cardiac and circulatory congenital anomalies
214 Digestive congenital anomalies
215 Genitourinary congenital anomalies
216 Nervous system congenital anomalies
217 Other congenital anomalies
218 Liveborn
219 Short gestation; low birth weight; and fetal growth retardation
220 Intrauterine hypoxia and birth asphyxia
221 Respiratory distress syndrome
222 Hemolytic jaundice and perinatal jaundice
223 Birth trauma
224 Other perinatal conditions
225 Joint disorders and dislocations; trauma-related
226 Fracture of neck of femur (hip)
227 Spinal cord injury
228 Skull and face fractures
229 Fracture of upper limb
230 Fracture of lower limb
231 Other fractures
232 Sprains and strains
233 Intracranial injury
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234 Crushing injury or internal injury
235 Open wounds of head; neck; and trunk
236 Open wounds of extremities
237 Complication of device; implant or graft
238 Complications of surgical procedures or medical care
239 Superficial injury; contusion
240 Burns
241 Poisoning by psychotropic agents
242 Poisoning by other medications and drugs
243 Poisoning by nonmedicinal substances
244 Other injuries and conditions due to external causes
245 Syncope
246 Fever of unknown origin
247 Lymphadenitis
248 Gangrene
249 Shock
250 Nausea and vomiting
251 Abdominal pain
252 Malaise and fatigue
253 Allergic reactions
254 Rehabilitation care; fitting of prostheses; and adjustment of devices
255 Administrative/social admission
256 Medical examination/evaluation
257 Other aftercare
258
Other screening for suspected conditions (not mental disorders or infec-
tious disease)
259 Residual codes; unclassified
260 E Codes: All (external causes of injury and poisoning)
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Figure 7: Healthcare expenditures by proximity to death, males by age
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